<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="37007">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02149121</url>
  </required_header>
  <id_info>
    <org_study_id>CT-P10 3.2</org_study_id>
    <secondary_id>2013-004555-21</secondary_id>
    <nct_id>NCT02149121</nct_id>
  </id_info>
  <brief_title>PK Similarity Prospective Phase 3 Study in Patients With Rheumatoid Arthritis</brief_title>
  <acronym>rituximab</acronym>
  <official_title>A Randomized, Controlled, Double-Blind, Parallel-Group, Phase 3 Study to Compare the Pharmacokinetics, Efficacy and Safety Between CT-P10, Rituxan and MabThera in Patients With Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celltrion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celltrion</source>
  <oversight_info>
    <authority>Austria: Austrian Medicines and Medical Devices Agency</authority>
    <authority>Germany: Paul-Ehrlich-Institut</authority>
    <authority>Hungary: National Institute for Quality and Organizational Development in Healthcare and Medicines</authority>
    <authority>Latvia: State Agency of Medicines</authority>
    <authority>Portugal: INFARMED, National Authority of Medicines and Health Products, IP</authority>
    <authority>Slovak Republic: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 3 Study to Compare the Pharmacokinetics, Efficacy and Safety between CT-P10,
      Rituxan and MabThera in Patients with Rheumatoid Arthritis.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>over the first 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>AUC0 last: area under the serum concentration-time curve covering both infusions, time to the last measurable concentration
AUC0-∞: area under the serum concentration-time curve covering both infusion, time zero to infinity
Cmax: maximum concentration after the second infusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy parameter</measure>
    <time_frame>at Week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>The change from Baseline in disease activity measured by DAS28 (CRP) at Week 24
DAS28, Hybrid ACR, Joint damage</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>CT-P10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rituximab, CT-P10(experimental drug), 1000mg by intravenous infusion. 2 infusions with a 2-week interval between the first and second infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rituxan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1000mg by intravenous infusion. 2 infusions with a 2-week interval between the first and second infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MabThera</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1000mg by intravenous infusion. 2 infusions with a 2-week interval between the first and second infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CT-P10</intervention_name>
    <description>1000mg by intravenous infusion. 2 infusions with a 2-week interval between the first and second infusion</description>
    <arm_group_label>Rituxan</arm_group_label>
    <arm_group_label>MabThera</arm_group_label>
    <other_name>MabThera</other_name>
    <other_name>Rituxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituxan</intervention_name>
    <description>1000mg by intravenous infusion. 2 infusions with a 2-week interval between the first and second infusion</description>
    <arm_group_label>CT-P10</arm_group_label>
    <arm_group_label>MabThera</arm_group_label>
    <other_name>rituximab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MabThera</intervention_name>
    <description>1000mg by intravenous infusion. 2 infusions with a 2-week interval between the first and second infusion</description>
    <arm_group_label>CT-P10</arm_group_label>
    <arm_group_label>Rituxan</arm_group_label>
    <other_name>rituximab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient is male or female between 18 and 75 years old, inclusive.

          2. Patient has a diagnosis of RA according to the revised 1987 ACR classification
             criteria (Arnett et al 1988) for at least 6 months prior to randomization.

          3. Patient has active disease as defined by the presence of 6 or more swollen joints (of
             66 assessed) and 6 or more tender joints (of 68 assessed), and serum CRP ≥1.5 mg/dL
             (≥15 mg/L) or an ESR ≥28 mm/hour.

          4. Patient has experienced an inadequate response to previous or current treatment with
             the anti-TNF agents infliximab

          5. Patient has a proper discontinuation period after treatment with interleukin-1
             receptor (IL-1R) antagonist, interleukin-6 receptor (IL-6R) antibody, or abatacept.

        Exclusion Criteria:

          1. Patient has taken more than 2 biologic agents.

          2. Patient has previously been administered Rituximab or participated in a Rituximab
             biosimilar study.

          3. Patient has allergies or hypersensitivity to murine, chimeric, human, or humanized
             proteins.

          4. Patient has current or past history of chronic infection with hepatitis B, hepatitis
             C, or infection with human immunodeficiency virus (HIV)-1 or -2 or who has a positive
             result to the screening test for these infections.

          5. Patient has an infection requiring oral antibiotics 2 weeks before randomization,
             parenteral injection of antibiotics 4 weeks before randomization, other serious
             infection 6 months before randomization, a history of recurrent herpes zoster or
             other chronic or recurrent infection 6 weeks before randomization.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>DaeHyun Yoo, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hanyang University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>SunYoung Yu</last_name>
    <phone>82 32 850 6559</phone>
    <email>SunYoung.Yu@celltrion.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>MinJi Kim</last_name>
    <phone>82 32 850 6591</phone>
    <email>MinJi.Kim2@celltrion.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CELLTRION,Inc.</name>
      <address>
        <city>Incheon</city>
        <zip>406840</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://www.celltrion.com/</url>
    <description>Company Homepage</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 28, 2014</lastchanged_date>
  <firstreceived_date>May 23, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
